Results 111 to 120 of about 57,554 (268)

Design, synthesis, molecular dynamics studies and biological evaluations of 4-hydroxy-5-pyrrolinone-3-carbohydrazides as HIV-1 integrase inhibitors

European Journal of Medicinal Chemistry Reports
Acquired immune deficiency syndrome (AIDS) diseases despite the efficacy of anti-HIV therapy, remain one of the human's most serious problems. Hence, the introduction of novel anti-HIV agents as first-line therapy is still required. HIV integrase lacking
Nafiseh Karimi, Amirreza Dowlati Beirami, Rouhollah Vahabpour Roudsari, Zahra Hajimahdi, Afshin Zarghi   +4 more
doaj   +1 more source

Cloning, Expression, and In Vitro Functional Activity Assay of phiC31 Integrase cDNA in Escherichia coli [PDF]

Cell Journal, 2013
Objective: The aim of present study was cloning and expression of phiC31 integrase cDNA in a bacterial expression vector. Thus, an intra molecular assay vector was applied to show in vitro activity of recombinant protein.Materials and Methods: In this ...
Mohammad Hadi Sekhavati, Mojtaba Tahmoorespur, Kamran Ghaedi, Kianoush Dormiani, Pharm, Mohammad Reza Nassiri, Yahya Khazaie, Mahboubeh Foruzanfar, Morteza Hosseini, Mohammad Hossein Nasr Esfahani   +8 more
doaj  

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades

Journal of Antimicrobial Chemotherapy, 2015
Objectives The aim of this study was to characterize the prevalence and patterns of genotypic integrase inhibitor (INI) resistance in relation to HIV-1 clade.
T. Doyle, D. Dunn, F. Ceccherini‐Silberstein, C. de Mendoza, Frederico Garcia, E. Smit, E. Fearnhill, A. Marcelin, J. Martinez-Picado, R. Kaiser, A. Geretti   +10 more
semanticscholar   +1 more source

Design, Synthesis and Structure-activity Studies of Rhodanine Derivatives as HIV-1 Integrase Inhibitors [PDF]

, 2010
Kavya Ramkumar, V. N. Yarovenko, A. S. Nikitina, И. В. Заварзин, Mikhail M. Krayushkin, L. V. Kovalenko, Adrian Esqueda, Srinivas Odde, Nouri Neamati   +8 more
openalex   +1 more source

Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy

HIV Medicine, Volume 27, Issue 2, Page 217-225, February 2026.
Abstract Objective Evaluate factors associated with discontinuation of long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and describe virologic outcomes in those that returned to oral antiretroviral therapy (ART). Methods This is a retrospective cohort study at a single‐centre primary care HIV clinic.
Tali Faggiano, Jeffrey Yin, Nimish Patel, Afsana Karim, Kari Abulhosn, Laura Bamford, Lucas Hill   +6 more
wiley   +1 more source

HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety

Drugs, 2020
K. Scarsi, J. Havens, A. Podany, Sean N. Avedissian, C. Fletcher   +4 more
semanticscholar   +1 more source

A family of developmentally excised DNA elements in Tetrahymena is under selective pressure to maintain an open reading frame encoding an integrase-like protein [PDF]

, 2000
Jill A. Gershan
openalex   +1 more source

Polypharmacy in HIV: Rethinking what counts and why it matters

HIV Medicine, Volume 27, Issue 2, Page 186-199, February 2026.
Abstract Polypharmacy, the concurrent use of multiple medications, presents a growing challenge in HIV care as people living with HIV age and experience earlier onset of age‐related co‐morbidities. However, how polypharmacy is defined and assessed in HIV research remains inconsistent.
Luxsena Sukumaran, Alan Winston, Catia Marzolini, Saye Khoo, Marta Boffito, Nadia Naous, Caroline A. Sabin   +6 more
wiley   +1 more source

The Cellular Protein Daxx Interacts with Avian Sarcoma Virus Integrase and Viral DNA To Repress Viral Transcription [PDF]

, 2005
James Greger, Richard A. Katz, Alexander M. Ishov, Gerd G. Maul, Anna Marie Skalka   +4 more
openalex   +1 more source

Temporal network analysis of comorbidities among people with HIV in South Carolina

HIV Medicine, Volume 27, Issue 2, Page 257-269, February 2026.
Abstract Introduction People with HIV experience a high rate of comorbidities that can complicate their health outcomes. Understanding the prevalence, interrelationships and temporal development of these comorbidities is crucial for improving health management and quality of life for people with HIV.
Yunqing Ma, Matthew Lohman, Monique J. Brown, Yichen Li, Xiaoming Li, Bankole Olatosi, Jiajia Zhang   +6 more
wiley   +1 more source